Related Experiment Video
Updated: Feb 12, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
The ORBITA trial: A point of view
Vitor Dornela de Oliveira1, Fernando Rabioglio Giugni1, Eduardo Bello Martins2
1Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Insights
The ORBITA trial found percutaneous coronary intervention (PCI) offered no exercise benefit over placebo for stable coronary artery disease (CAD) patients. This challenges current guidelines recommending PCI for symptom relief in such cases.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Stable coronary artery disease (CAD) treatment aims to improve prognosis and relieve symptoms.
- Revascularization is indicated for symptomatic CAD patients refractory to drug treatment per guidelines.
- Previous studies suggested angioplasty benefits angina and functional capacity in symptomatic stable CAD.
Purpose of the Study:
- To critically evaluate the ORBITA trial's findings regarding percutaneous coronary intervention (PCI) in stable CAD.
- To discuss the methodological issues, limitations, and clinical applicability of the ORBITA trial.
Main Methods:
- The ORBITA trial investigated contemporary percutaneous coronary intervention (PCI) versus a placebo procedure.
- The study population included patients with single-vessel stable CAD.
- Exercise tolerance was a primary endpoint.
Main Results:
- The ORBITA trial demonstrated no significant benefit of PCI over a placebo procedure in improving exercise tolerance.
- This finding contrasts with previous assumptions about angioplasty's efficacy in symptomatic stable CAD.
Conclusions:
- The ORBITA trial raises questions about the routine use of PCI for symptom relief in stable CAD.
- Methodological considerations and clinical applicability of the trial's results require careful discussion.
Abstract:
Treatment of stable coronary artery disease (CAD) relies on improved prognosis and relief of symptoms. National and international guidelines on CAD support the indication for revascularization in patients with limiting symptoms and refractory to drug treatment. Previous studies attested the efficacy of angioplasty to improve angina as well as the functional capacity of patients with symptomatic stable CAD. The ORBITA trial, recently published in an international journal, showed no benefit in terms of exercise tolerance compared to a placebo procedure in a population of single-vessel patients undergoing contemporary percutaneous coronary intervention. In this point of view article, the authors discuss the ORBITA trial regarding methodological issues, limitations and clinical applicability.
Related Concept Videos
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Econometric Views (EViews)
Cranial Bones: Lateral View
The temporal bone forms the lower lateral side of the skull. The temporal bone is subdivided into several regions. The flattened upper portion is the squamous portion of the temporal bone. Below this area and projecting anteriorly is the zygomatic process of the temporal bone, which forms the posterior portion of the zygomatic arch. Posteriorly is the mastoid portion of the temporal bone. Projecting...
Revisionist Views of Adolescent and Adult Cognition

